North Dakota legislation · 69th Legislative Assembly
North Dakota HB1543: AN ACT to provide for a legislative management study regarding prescription drug pricing and the maximum fair price as determined by the federal government.
Status: Signed into law, March 27, 2025
What the bill says
An act to provide for a legislative management study regarding prescription drug pricing and the maximum fair price as determined by the federal government.
From the enrolled text, March 21, 2025:
AN ACT to provide for a legislative management study regarding prescription drug pricing and the maximum fair price as determined by the federal government. SECTION 1. LEGISLATIVE MANAGEMENT STUDY - PRESCRIPTION DRUG PRICING. 1. During the 2025-26 interim, the legislative management shall consider studying prescription drug pricing and the maximum fair price for a drug as published by the secretary of the United States department of health and human services. 2. The study must include consideration of federal drug price negotiations under the Federal Inflation Reduction Act of 2022 [Pub. L. 117-169; 26 U.S.C. 55 et seq.] and overlap with current drugs paid for by the public employees retirement system to determine usage and potential cost-savings to the state and consumers. 3. The study must include input b. The insurance commissioner; c. The state board of pharmacy; and d. Other stakeholders. 4. The legislative management shall report its findings and recommendations, together with any legislation necessary to implement the recommendations, to the seventieth legislative assembly. H. B. NO. 1543 - PAGE 2 ____________________________ ____________________________ Speaker of the House President of the Senate ____________________________ ____________________________ Chief Clerk of the House Secretary of the Senate This certifies that the within bill originated in the House of Representatives of the Sixty-ninth Legislative Assembly of North Dakota and is known on the records of …
Sponsors
- Lisa Meier (R, 32) · primary sponsor
- Karen Anderson (R, 19)
- Macy Bolinske (R, 40)
- Sean Cleary (R, 35)
- Dick Dever (R, 32)
- Gretchen Dobervich (D, 11)
- Kathy Frelich (R, 15)
- Patrick Heinert (R, 32)
- Kathy Hogan (D, 21)
- Dawson Holle (R, 31)
- Karen Rohr (R, 31)
- Robin Weisz (R, 14)
Latest actions
- : Filed with Secretary Of State 03/26
- : Signed by Governor 03/25
- : Sent to Governor
- : Signed by Speaker
- : Signed by President
- : Second reading, passed, yeas 89 nays 4
- : Concurred
- : Returned to House (12)
- : Second reading, passed as amended, yeas 44 nays 1
- : Amendment adopted, placed on calendar
Votes
- Final Passage (March 18, 2025): 89 yea, 4 nay, passed
- Final Passage (March 10, 2025): 44 yea, 1 nay, passed
- Final Passage (February 10, 2025): 86 yea, 4 nay, passed
Common questions
- What is HB1543?
- HB1543 is a bill in the North Dakota Legislature (69th Legislative Assembly): AN ACT to provide for a legislative management study regarding prescription drug pricing and the maximum fair price as determined by the federal government.
- What does HB1543 do?
- In its own words: An act to provide for a legislative management study regarding prescription drug pricing and the maximum fair price as determined by the federal government.
- What is the status of HB1543?
- Signed into law as of March 27, 2025. Latest action: Filed with Secretary Of State 03/26 (March 27, 2025).
- Who sponsored HB1543?
- Lisa Meier (R, 32), with 11 co-sponsors.
- Where is the official record for HB1543?
- On the North Dakota Legislature website: https://ndlegis.gov/assembly/69-2025/regular/bill-overview/bo1543.html
Source: official North Dakota record. Tracked by Delilah, AI for legislation across all 50 states and Congress.